ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Testing the effects of topical skin care products on Tumor Treating Fields (TTFields) adhesiveness of arrays and delivery of electric currents.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Impact of tumor treating fields on overall and progression-free survival in newly diagnosed glioblastoma: A systematic review and meta-analysis.Neurosurgical review · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTumor Treating Fields (TTFields) therapy is an approved cancer treatment, delivered to patients continuously via arrays applied to the skin surrounding the tumor region. The delivery of treatment by skin-adherent arrays creates an inherent risk of skin irritation. Implementing proactive measures for skin care with appropriate agents is necessary to maintain patient quality-of-life and increase device usage for better treatment effectiveness. The goal of this study was to examine the effects of commercially available skin care products on array adhesiveness and electric current delivery, to determine which may be used to alleviate device-related skin irritation without compromising treatment effectiveness.
methodsWe tested skin care products that are customary for the treatment of skin adverse events (AEs), including skin barriers, topical corticosteroids, anti-itching products, wound healing agents, and topical antimicrobials. We also tested moisturizers, recommended for preserving good skin health. We performed a wide screen on 34 compounds in animal models, and then validated the results in humans for 8 of the compounds.
resultsThe preclinical tests identified 24 compounds that did not interfere with TTFields delivery, coming from the various medical use groups. Those that significantly reduced array adhesiveness and electrical conduction contained an electrical insulator/lipid component as the major ingredient. The results from the human study were in concordance with the preclinical results.
conclusionsThis study identified, under controlled conditions, a selection of commercially available skin care products that do not compromise TTFields delivery and hence may serve as candidates for managing skin AEs in TTFields-treated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.